Drug Database
RA

rabies vaccine

✓ Approved

China National Biotec Group · 疫苗 · 疫苗

什么是 rabies vaccine?

rabies vaccine 是一种疫苗,由China National Biotec Group研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intramuscular (IM) Injection。

药物档案

公司China National Biotec Group
药物类别疫苗
给药途径Injectable (Others), Intramuscular (IM) Injection
状态Approved

治疗适应症

rabies vaccine 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Infections and infestationsRabies✓ Approved

相关研究文献

PubMedNPJ vaccines2026-11-19

SARS-CoV-2 RBD fusion ameliorates enhanced disease induced by RSV G CCD mRNA vaccine in BALB/c mice.

Sun Yufang Y, Xie Ying Y, Liu Lian L, Yang Huijie H et al.

Respiratory syncytial virus (RSV) is a primary pathogen responsible for lower respiratory tract infections in both infants and the elderly. However, vaccine development has been consistently hampered by the risk of vaccine-enhanced disease (VED), while the role of the RSV attachment (G) glycoprotein has long been overlooked. Using an mRNA vaccine platform, this study systematically evaluated the roles of two critical RSV G protein domains-the central conserved domain (CCD) and the mucin-like domains-in mediating immune protection and VED. Results indicate that the mucin-like domains confer no protection and induce marked VED. Surprisingly, although CCD immunization elicits potent humoral immunity and significantly reduces viral load, it also induces Th2-biased responses and exacerbates pulmonary inflammation following RSV challenge. However, fusion of CCD with the receptor-binding domain (RBD) of SARS-CoV-2 in an mRNA vaccine (CCD + RBD) successfully redirected the Th2-biased immune responses toward a balanced Th1/Th2 profile, while significantly attenuating CCD-induced immunopathology. CD8⁺ T-cell depletion and adoptive-transfer experiments further supported a contribution of RBD-responsive CD8⁺ T cells to the reduction in pathology. These findings provide proof of concept that heterologous antigen fusion can reshape CCD-associated immunopathology in a BALB/c RSV challenge model.

PMID 43052326
阅读全文 →
PubMedNPJ vaccines2026-11-19

Chitosan-based nanoparticles encapsulating Nocardia seriolae lysates confer protection against nocardiasis through immersion vaccination in Micropterus salmoides.

Li Lijuan L, Liu Zhimin Z, Sun Yihan Y, Li Kesong K et al.

Development of effective vaccines with convenient administration, including oral immunization or immersion, to control pathogens is important for the sustainability of aquaculture. Nocardia seriolae was found to harm over 40 types of cultured marine and freshwater species, especially in Micropterus salmoides and Channa argus, causing more than 30% mortality. In this study, a novel isolate of N. seriolae (B20200724) growing fast and manifesting comparative virulence with other N. seriolae was identified from diseased M. salmoides. Chitosan-based nanoparticles encapsulating whole-cell lysates of N. seriolae B20200724 with great mucoadhesive features were prepared for evaluation of the protective effect against N. seriolae in M. salmoides. Chitosan-based nanoparticles via immersion vaccination boost the innate immune response, elicit the expression of Th2 cytokines and high-titer antibody responses, ultimately conferring a 45% relative protection rate against N. seriolae infection. These findings provide a novel vaccine candidate and verify a convenient immunization route, which promotes the potential of the vaccine against fish nocardiosis for commercial use.

PMID 43052343
阅读全文 →
PubMedWellcome open research2026-11-19

Did the emergence of the Omicron variant impact the COVID-19 vaccine acceptance in the Arab world? A Twitter-based sentiment analysis.

Dimashkieh Chehab Nada N

Low vaccine acceptance constitutes a major obstacle for achieving herd immunity against coronavirus disease 2019 (COVID-19). Data on COVID-19 show a significant rise in the number of cumulative cases in Arab countries where vaccine uptake is lower than the uptake at the global level for the 2021-2022 period. The aim of this study is to analyze sentiments related to vaccine acceptance before and after the emergence of the COVID-19 Omicron variant in the Arab-speaking world. Tweets were collected before and after the Omicron emergence period in the Arab-speaking world using Python-enabled CAMeL Tools (Arabic Natural Language Processing toolkit) libraries. A sentiment analysis on COVID-19 vaccines using Arabic hashtags and a sentiment analysis by city were conducted. Two data sets pre-Omicron and post-Omicron tweets exhibited a difference in sentiments marking a shift towards less negativity and more neutrality. Sentiments by city showed most tweets in both periods coming from Riyadh and Jeddah in Saudi-Arabia, and from Salt in Jordan. Despite the limitations of the study, the change in sentiments detected by the study may suggest more vaccine acceptance which raises some hope and perhaps a higher vaccine uptake in the future. The sentiments by city findings may help in the design of future research.

PMID 43053887
阅读全文 →
PubMedCancer immunology, immunotherapy : CII2026-11-19

A phase 1 study of VAC85135, a neoantigen vaccine regimen targeting calreticulin and JAK2 mutations, in combination with ipilimumab in patients with myeloproliferative neoplasms.

Otoukesh Salman S, Psaila Bethan B, Kuykendall Andrew A, Gerds Aaron T AT et al.

Disease-specific somatic mutations (mut) in calreticulin (CALR) and JAK2 (JAK2V617F) are drivers of myeloproliferative neoplasms (MPNs), causing generation of immunogenic peptide epitopes hypothesized to be vaccine-targetable neoantigens. VAC85135, a heterologous prime-boost vaccine regimen comprising adenoviral and vaccinia vectors encoding polypeptides specific to mutCALR and JAK2V617F, concurrent with anti-CTLA-4, ipilimumab, was investigated in a phase 1 study. Fourteen (myelofibrosis [MF], n = 10, essential thrombocythemia [ET], n = 4; mutCALR, n = 12, JAK2V617F, n = 2) patients were enrolled across three cohorts. A safety lead-in cohort (C0) received VAC85135 alone by intramuscular injection. Following acceptable tolerability, intramuscular VAC85135 was co-administered with intravenous ipilimumab: 1 mg/kg (C1) or 3 mg/kg (C2). Antigen-specific T-cell immune responses were analyzed by IFN-γ ELISpot. Clinical responses were evaluated per IWG-MRT-ELN criteria. Treatment-related adverse events were reported in 64.3% of patients; mostly Grade 1/2. Positive immune responses to mutCALR were observed post-vaccination in 5/14 (35.7%) patients. Immune response was maintained in one C0 patient over the treatment duration starting after dose 3; responses in four C1 patients were transient and observed after dose 7 in 2/4 patients. No patients had reduced mutCALR or JAK2V617F mutant allele burden at any post-vaccination timepoint. Consistent reductions in reticulin fibrosis were not observed in post-vaccination bone marrow biopsies. Best overall response was stable disease in nine patients with MF and no response in four patients with ET. The absence or delayed onset of immune response in most patients suggest VAC85135 was poorly immunogenic and unable to generate productive CALR or JAK2 neoantigen antitumor immunity.ClinicalTrials.gov identifier: NCT05444530.

PMID 43052517
阅读全文 →
PubMedNPJ vaccines2026-11-19

Efficacy, safety, and biodistribution of intranasally delivered adenoviral COVID-19 vaccine in hamsters.

Laham-Karam N N, Mäkinen P P, Koivulehto E E, Gurzeler E E et al.

Coronavirus disease 2019 (COVID-19) continues to cause outbreaks around the world despite the vast COVID-19 vaccination programs. Thus, it is important to continue developing better vaccines to protect vulnerable populations. Here, we studied the efficacy, safety, persistence and biodistribution of an adenovirus-based COVID-19 vaccine delivered intranasally. Our results confirmed that mucosal delivery leads to effective protection against infection in hamsters. A comparative study of different adenoviral vectors demonstrated that specifically Ad5-S-3M, expressing the SARS-CoV-2 spike glycoprotein ectodomain with inclusion of three common receptor binding domain mutations, induced a robust humoral immune response and effectively protected hamsters from SARS-CoV-2 infection. In addition, longitudinal analysis of vaccinated hamsters' tissues demonstrated durable vaccine transgene expression and persistent vector DNA in the nasal turbinates. This persistence may be beneficial in increasing the duration of immunity. Expression of the S-3M did not cause any aberrant changes in the hamster tissues and resulted in very few changes in cellular mRNA expression in target tissues. Safety and biodistribution assessment demonstrated restricted non-target tissue distribution of intranasally delivered vector and no significant changes in clinical blood chemistry, underlining the safety of the vaccine. These results further support that intranasal delivery is a promising approach for mucosal vaccine administration against respiratory infection pathogens and extend our knowledge of Adeno-vector persistence.

PMID 43052363
阅读全文 →
PubMedNPJ vaccines2026-11-19

Influenza neuraminidase as adjuvanted protein or mRNA vaccine protects mice against influenza A and B virus challenge.

Portela Catani João Paulo JP, Smet Anouk A, Ysenbaert Tine T, Amelinck Laura L et al.

Neuraminidase (NA) is an underutilized influenza vaccine antigen despite its recognized contribution to protective immunity. Here, we compared the immunogenicity and protective potential of multiple NA antigens delivered as an adjuvanted recombinant tetrameric protein or as mRNA-LNP encoding full-length NA in naïve mice. Both vaccine types induced robust neuraminidase-inhibiting (NAI) antibody responses and conferred protection to mice challenged with antigenically homologous influenza A or B viruses. However, only immunization with NA-encoding mRNA-LNP protected against challenge with a heterologous HxN2 virus, whereas immunization with recombinant NA was associated with earlier onset of weight loss following heterologous HxN2 virus challenge. Passive transfer of immune serum revealed that protection induced by mRNA immunization can be transferred by serum, and that early onset of weight loss is not induced by recombinant NA-derived sera; on the contrary, partial protection is achieved. Finally, NAI assays against a panel of antigenically distinct HxN2 viruses showed similar breadth of inhibition.

PMID 43052397
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多rabies vaccine